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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.033Cannabinoid receptor 2 (CB2) is highly expressed in immune cells and stimulation decreases inﬂam-
matory responses. We tested the idea that selective CB2 activation in human monocytes suppresses
their ability to engage the brain endothelium and migrate across the blood-brain barrier (BBB), pre-
venting consequent injury. Intravital videomicroscopy was used to quantify adhesion of leukocytes to
cortical vessels in lipopolysaccharide-induced neuroinﬂammation, after injection of ex vivo CB2e
activated leukocytes into mice; CB2 agonists markedly decreased adhesion of ex vivo labeled cells
in vivo. In an in vitro BBB model, CB2 activation in monocytes largely attenuated adhesion to and
migration across monolayers of primary human brain microvascular endothelial cells and diminished
BBB damage. CB2 stimulation in monocytes down-regulated active forms of integrins, lymphocyte
function-associated antigen 1 (LFA-1), and very late antigen 4 (VLA-4). Cells treated with CB2 agonists
exhibited increased phosphorylation levels of inhibitory sites of the actin-binding proteins coﬁlin and
VASP, which are upstream regulators of conformational integrin changes. Up-regulated by relevant
stimuli, Rac1 and RhoA were suppressed by CB2 agonists in monocytes. CB2 stimulation decreased
formation of lamellipodia, which play a key role in monocyte migration. These results indicate that
selective CB2 activation in leukocytes decreases key steps in monocyteeBBB engagement, thus sup-
pressing inﬂammatory leukocyte responses and preventing neuroinﬂammation. (Am J Pathol 2013,
183: 1548e1558; http://dx.doi.org/10.1016/j.ajpath.2013.07.033)Supported in part by NIH grants R01 AA015913 and R01 MH65151
(Y.P.) and by the Intramural Research Program of the NIH-NIAAA (P.P.).Two subtypes of receptors mediate most cannabinoid
actions: the CB1 receptor, located in the central nervous
system and in peripheral tissues,1,2 and the CB2 receptor,
found in the periphery and mainly in immune cells
expressing high levels of CB2.3,4 The level of their
expression is dependent on the activation state of the cell
and the type of stimulus.5 Cannabinoids modulate immune
functions and therefore have therapeutic potential for thestigative Pathology.
.treatment of inﬂammatory diseases.4,6,7 Recruitment of
inﬂammatory cells and their adhesion and transendothelial
migration are triggered by local production of cytokines,
chemokines, and adhesion molecules.6 Our research group
recently showed that CB2 activation reduces expression of
CB2 Attenuates Monocyte BBB Migrationadhesion molecules in brain endothelium, decreasing
leukocyte engagement and recruitment.8 Cannabinoids can
inhibit chemokine-induced chemotaxis of various immune
cells.7,9,10 However, the mechanisms underlying the effects
of cannabinoids in human monocytes, such as adhesion and
migration, are largely unknown.
The monocyte-macrophage system exists in at least two
distinct phenotypes of differentiation: proinﬂammatory (M1)
and anti-inﬂammatory (M2).11 Extensive data suggest that
microglial activity is not always adequate to support repair of
the central nervous system and that recruitment of myeloid
cells (M2) from the blood stream contributes to recovery after
spinal cord injury.12 Microglia restricted amyloid-b plaques
in a mouse model of Alzheimer’s disease13,14 and reversed
paralysis in an experimental autoimmune encephalomyelitis
model for multiple sclerosis.15 However, because the CNS is
an immune privileged site, it is assumed to exclude excessive
leukocyte trafﬁcking,16,17 especially the proinﬂammatory
(M1) type, which is prevalent during infection.18,19
Circulating leukocytes are recruited to sites of injury,
infection, and inﬂammation by well-coordinated sequential
steps (including tethering, rolling, arrest, ﬁrm adhesion, and
migration across the endothelium20,21) mediated by selectin
and integrin proteins.21 Many integrins are expressed in
an inactive state.22 Integrin ligand binding is rapidly and
transiently activated by cytoplasmic signals initiated by stim-
ulation of diverse cell surface receptors, such as cytokines
(inside-out signaling), or by ligand binding to integrin or
integrin cross-linking (outside-in signaling).21,23 Development
of antibodies that detect expression of active integrin confor-
mation has led to better understanding of the interactions
between leukocytes and the endothelium.24 Leukocyte integ-
rins, like lymphocyte function-associated antigen-1 (LFA-1)
and very late antigen 4 (VLA-4), recognize their respective
endothelial adhesion molecules (ICAM-1 and VCAM-1) and
stabilize adhesion under constant shear stress forces. Using
HUTS21 and MEM-148 (which detect the active conforma-
tion of VLA-4 and LFA-1, respectively24e26) and relevant
stimuli, we analyzed the effects of CB2 activation on the
processes regulating integrin conformational changes during
monocyte adhesion and migration.
In the present study, we tested CB2 agonists in a lipo-
polysaccharide (LPS)-stimulated encephalitis model to
evaluate leukocyteeendothelial cell interactions in brain
microvessels.8 Selective ex vivo CB2 activation in leuko-
cytes resulted in a signiﬁcant diminution in leukocytee
endothelial cell engagement. Conversely, there was a 50%
increase in leukocyte adhesion when leukocytes from mice
lacking the CB2 receptor (CB2ko) were transferred to wild-
type (WT) CB2-expressing animals. Next, we showed that
CB2 activation in monocytes signiﬁcantly reduced adhesion
and migration in a human in vitro blood-brain barrier (BBB)
model, preserving barrier function. CB2 agonists reduced
integrin activation and lamellipodia formation in primary
monocytes via inhibition of small GTPases (RhoA and
Rac1) and effects on cytoskeletal proteins. These resultsThe American Journal of Pathology - ajp.amjpathol.orgdemonstrate anti-inﬂammatory effects of selective CB2
agonists in monocytes and suggest treatment opportunities
for chronic inﬂammatory disorders within and outside of the
central nervous system.
Materials and Methods
Reagents and Cells
Recombinant hTNF-a and hMCP1/CCL2 were from R&D
Systems (Minneapolis,MN). Four selectiveCB2 agonistswere
used: JWH133 [(6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,
10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran], GP1a
[(N-piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-
methylindeno[1,2-c]pyrazole-3-carboxamide], AM1241
[(2-Iodo-5-nitrophenyl) (1-([1-methyl-2-piperidin]methyl)-
1H-indol-3-yl)methanone], and O-1966 (1-[4-(1,1-dimethyl-
heptyl)-2,6-dimethoxy-phenyl]-3-methyl-cyclohexanol).
JWH133andGP1awere fromTocrisBioscience (Bristol, UK),
AM1241 from Cayman Chemical (Ann Arbor, MI), and O-
1966 from Organix (Woburn, MA). Phorbol 12-myristate 13-
acetate (PMA) and the selective CB2 antagonist SR144528
[5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyr-
azole-3-carboxamide] were from Cayman Chemical. LPS
from Escherichia coli 0111:B4 was from Sigma-Aldrich (St.
Louis, MO).
Primary brain microvascular endothelial cells (BMVECs),
isolated from vessels from brain resection tissue (showing no
abnormalities) of patients undergoing surgery for treatment of
intractable epilepsy, were supplied by Michael J. Bernas and
Dr. Marlys H. Witte (University of Arizona, Tucson, AZ) and
were maintained as described previously.27 Primary human
monocytes, supplied by the Human Immunology Core
facility of the University of Pennsylvania (Philadelphia, PA),
were maintained as described previously27 and were used
within 24 hours of isolation. The human myeloid leukemia
cell line U937 (ATCC, Manassas, VA) was maintained as
described previously.27
In all experiments, primary monocytes or U937 mono-
cytic cells were pretreated with CB2 agonists (O-1966,
JWH133, or GP1a at 10 mmol/L or AM1241 at 2 mmol/L)
for 30 minutes, except as otherwise stated. CB2 agonists and
antagonists were dissolved in ethanol and then diluted into
growth medium. In all experiments, for nontreated (NT)
cells only diluent was added, without any CB2 agonist or
antagonist. Treatment with agonists did not cause any toxic
effects on cell viability as determined by a LIVE/DEAD cell
viability assay (Life Technologies, Carlsbad, CA) (data not
shown).
Animals
Intravital videomicroscopy (IVM) was performed on 8-
week-old male C57BL/6 or CB2ko mice (strain B6.129P2-
Cnr2tm1Dgen/J) purchased from the Jackson Laboratory (Bar1549
Rom et alHarbor, MI). In vivo experiments were conducted in accor-
dance with guidelines approved by the Temple University
Institutional Animal Care and Use Committee.
Ex Vivo Treatment and Labeling of Leukocytes and IVM
IVM for in vivo leukocyte adhesion was performed on
animals subjected to craniotomy and cranial window
implantation as described previously.8
Leukocytes were isolated from donor mice using 1 RBC
lysis buffer (eBioscience, San Diego, CA), according to the
manufacturer’s instructions. For ex vivo treatment, 2  106
cells were treated with CB2 agonist, washed with PBS,
stained with 1 mmol/L calcein-AM (Life Technologies),
washed, and resuspended in PBS for injection. Before IVM,
animals were treated with 6 mg/kg LPS for 4 hours, anes-
thetized, immobilized, and injected intraorbitally with 100 mL
calcein-AMelabeled cells.
Leukocytes were visualized by ﬂuorescent light [495 nm
excitation for calcein-AM and 601 nm for rhodamine 6G
(Sigma-Aldrich)] in cerebral vessels through the cranial
window using a SteREO Discovery V20 epiﬂuorescence
microscope (Carl ZeissMicroscopy, Jena, Germany) equipped
with an AxioCam MR digital camera and analyzed using
AxioVision 4.8 imaging software. A 30-second video (time-
series image set between 16 and 20 frames per second) was
captured using a digital high-speed recorder. Adherent leuko-
cytes were deﬁned as the number of leukocytes ﬁrmly attached
to the endothelium that did not change location during the
observation period, scored as the number of cells per square
millimeter of the vascular surface area, calculated from the
diameter and length of the vessel segment under observation.
Monocyte Adhesion Assays
Freshly isolated human monocytes were treated with or
without CB2 agonist. Treatments were removed from the
monocytes before calcein-AM labeling; adhesion assays
were performed as described previously.27 Fluorescence of
adherent monocytes was measured using a Synergy 2 plate
reader (BioTek Instruments, Winooski, VT) and expressed
as mean fold adhesion, calculated as the number of adherent
monocytes for each experimental condition divided by the
basal adhesion of the untreated control.
Transendothelial Migration Assays
Transendothelial migration assays were performed as
described previously,27 with monocytes treated and labeled
similarly to the adhesion assay. The number of migrated
monocytes was determined using ImageJ software version
1.43u (NIH, Bethesda, MD) and expressed as fold differ-
ence in migration from triplicate determinations, calculated
as the number of migrated monocytes for each experimental
condition divided by the number of migrated monocytes in
the untreated, no-chemoattractant control.1550TEER
Monocytes were treated with or without CB2 agonist. Cells
were rinsed, and the medium was replaced before addition
of the monocytes (1  105 cells per well) to the electrical
cell-substrate impedance sensing (ECIS) array. Trans-
endothelial electrical resistance (TEER) was measured using
a 1600R ECIS system (Applied BioPhysics, Troy, NY) as
described previously27 and was expressed as the mean
percent change from baseline TEER from at least two
independent experiments (four to six replicates each).
Conformational Changes of VLA-4 and LFA-1 Integrins
We used the VLA-4especiﬁc ligand LDV (L-leucyl-L-
aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine; Tocris
Bioscience) as a speciﬁc stimulator of active VLA-4 con-
formation. VLA-4eactivated conformation, detected by
HUTS21, was measured by ﬂuorescence-activated cell
sorting as described previously.24,27
Primarymonocytes (0.5 106/mL) in RPMI 1640e1% fetal
bovine serum were treated with or without CB2 agonists and
then stimulated with 100 ng/mL PMA for 1 hour. Cells were
placed on ice and ﬁxed with 4% formaldehyde. LFA-1 con-
formation, detected by MEM-148 antibody, was measured as
described previously.25 Data were acquired with a FACSCanto
II ﬂow cytometer (BDBiosciences, San Jose, CA) and analyzed
with FlowJo software version 8.7 (Tree Star, Ashland, OR).
RhoA and Rac1 GTPase Activity Assay
RhoA and Rac1 GTPase activity was measured in cell lysates
prepared from primary monocytes or U937 cells (untreated or
pretreated with CB2 agonists) by stimulation with 100 ng/mL
PMA or 100 ng/mL CCL2, known activators of GTPases28 or
with 12 nmol/L LDVpeptide. For a positive control, cells were
stimulated with 1 mg/mL CN04 (Cytoskeleton, Denver, CO).
To inhibit RhoAorRac1GTPase activity, cells were pretreated
with speciﬁc inhibitors [1 mg/mL CT04 (Cytoskeleton) or 75
mmol/L NSC23766 (EMD Millipore, Billerica, MA), respec-
tively]. To measure RhoA and Rac1 GTPase activity, G-LISA
RhoA and G-LISA Rac1 activation assay kits (Cytoskeleton)
were used according to the manufacturer’s instructions.
Western Blotting
For signaling studies, 5 106 U937 cells were suspended in 1
mL of RPMI 1640e1% fetal bovine serum, treated with or
without CB2 agonist and stimulatedwith 12 nmol/L LDV, 100
ng/mL CCL2, or 100 ng/mL PMA for 1 hour at 37C. Then
cells were placed on ice and lysed in radioimmunoprecipitation
assay buffer. Isolated proteins were separated on SDS-PAGE
as described previously.27 Antiep-coﬁlin and antiep-VASP
(Cell SignalingTechnology,Danvers,MS) and antieb-tubulin
protein loading control (Santa Cruz Biotechnology, Santa
Cruz, CA) were used to detect target proteins. Bound primaryajp.amjpathol.org - The American Journal of Pathology
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Figure 1 Selective CB2 activation in leukocytes reduced their adhesion
in LPS-induced encephalitis. A: Experimental design. B: Quantitation of
leukocyte ﬁrm adhesion (not rolling) during 30 seconds of observation
(ex vivo treated, calcein-AMelabeled leukocytes). Leukocytes were treated
ex vivo with or without CB2 agonist (2 mmol/L AM1241 or 10 mmol/L
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SR144528 (SR144)]. Representative images from a video of leukocytes
labeled with calcein-AM are shown in Supplemental Figure S1. Data are
expressed as means  SEM. nZ 4 to 6 animals per treatment. *P < 0.05.
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CB2 Attenuates Monocyte BBB Migrationantibodies were exposed to ﬂuorescent IRDye 680 or IRDye
800 infrared secondary antibodies (LI-COR Biosciences,
Lincoln, NE) and were detected using the LI-COR Odyssey
imaging system.
Visualization of Lamellipodia
For immunoﬂuorescence studies, cells were treated and stim-
ulated as described above for signaling experiments and then
were ﬁxed, permeabilized, and stained as described previ-
ously.27 Images of twenty cells per treatment were taken at
63 magniﬁcation (1024  1024 pixel area) using a Leica
SP5 confocal laser scanningmicroscope (LeicaMicrosystems,
Wetzlar, Germany) and processed with Adobe Photoshop CS3
software (Adobe Systems, San Jose, CA). The area (in pixels)
of each lamellipodium per cell was measured using ImageJ
software (NIH), and the average lamellipodium area per cell in
each captured image was used for statistical analysis.
Statistical Analysis
Multiple group comparisons were performed by one-way
analysis of variance with Dunnett’s post hoc tests (adhesion,
migration, ﬂuorescence-activated cell sorting, and G-LISA
assay). Statistical analyses were performed using GraphPad
Prism software version 5 (GraphPad Software, La Jolla,The American Journal of Pathology - ajp.amjpathol.orgCA). Differences were considered signiﬁcant at P < 0.05.
Data are expressed as means  SEM from experiments
performed multiple times.
Results
CB2 Activation Decreases Leukocyte Adhesion in
Surface Cortical Vessels
Previous studies have demonstrated increased expression of
CB2 in human brain tissues affected by amyotrophic lateral
sclerosis, Alzheimer’s disease, and multiple sclerosis.7,29
CB2 is highly expressed on leukocytes, and expression is
up-regulated by proinﬂammatory stimuli.30 CB2 activation
reduced inﬂammation in preclinical disease models.7,29,31e35
We hypothesized that CB2 on leukocytes could serve as
a target for the anti-inﬂammatory effects of CB2 agonists via
decreasing leukocyte engagement of endothelium and BBB
injury. To investigate this idea, we tested whether CB2
activation reduces leukocyte adhesion in vivo in an animal
model of systemic inﬂammatory response. We used IVM for
surveillance of cerebral vascular changes and leukocytee
endothelial cell interactions.8 To evaluate the effects of CB2
activation on leukocytes only (ﬁrm leukocyte adhesion),
leukocytes isolated from WT mice were treated ex vivo with
selective CB2 agonists, stained with calcein-AM, washed,
and injected into LPS-treated mice (Figure 1A). Compared1551
Rom et alwith control mice, animals treated with LPS showed a 20-
fold increase in ﬁrm adhesion of ex vivo labeled cells. The
CB2 agonists GP1a, JWH133, and AM1241 decreased
leukocyte adhesion by 96%, 91%, and 50%, respectively
(Figure 1B and Supplemental Figure S1). Autologous
leukocytes (rhodamine-labeled) showed a uniform 20-fold
increase in ﬁrm adhesion (Supplemental Figure S2), which
is indicative of the expected inﬂammatory response. The ratio
of injected versus autologous leukocytes adherent to brain
microvessels in LPS-treated mice ranged from 1:8 to 1:10.
Pretreatment of leukocytes with the CB2 antagonist and the
inverse agonist SR144528 partially reversed the effects of the
selective CB2 agonists (Figure 1B). These results indicate
major anti-inﬂammatory effects of selective CB2 activation
in leukocytes in vivo.
Next, to conﬁrm involvement of the CB2 receptor, we
performed adoptive transfer of WT and CB2ko leukocytes to
WT and CB2ko recipient mice. Leukocytes were isolated
from WT or CB2ko donor mice, labeled with calcein-AM,
washed, and injected into recipient mice (Figure 2A). CB2ko
leukocytes transferred into WT recipient mice exhibited an
approximately 100% increase in adhesion, compared with
WT, CB2-expressing leukocytes; in similar experiments with
CB2ko recipients, there was a 40% increase in adhesion of
CB2ko leukocytes, compared with WT leukocytes
(Figure 2B and Supplemental Figure S3). WT leukocytes
exhibited increased adhesion in CB2ko animals versus WT
animals treated with LPS. Leukocyte adhesion observed in
the same animals injected with autologous leukocytes par-
alleled results in adoptive transfers, with a 40% increase in
adhesion in CB2ko animals, compared with WT animals
(Supplemental Figure S4).0
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1552CB2 Stimulation in Monocytes Diminishes Their
Adhesion to Brain Endothelium, Diminishes
Transendothelial Migration, and Attenuates BBB Injury
Next, we determined whether CB2 stimulation decreases
monocyte adhesion to brain endothelium. TNF-a induced
a twofold increase in the number of monocytes attaching to
BMVECs, compared with baseline, and the addition of CB2
agonist pretreatment reduced the adhesion of monocytes to
BMVECs by approximately 100% (GP1a, JWH133, and
AM1241), compared with TNF-a alone (untreated control)
(Figure 3A). Using an in vitro BBB model, we tested
whether CB2 activation in primary human monocytes
prevents their passage across BMVEC monolayers toward
CCL2. Application of CCL2 to the lower chamber of BBB
constructs increased monocyte migration 4.9-fold. CB2
agonist pretreatment of monocytes then attenuated this
increased monocyte migration across endothelial mono-
layers by approximately 60% (Figure 3B).
Brain endothelial engagement by leukocytes and subsequent
migration across the BBB leads to barrier damage. We
hypothesized that because CB2 activation in monocytes
reduced their ability to attach and migrate through BMVEC
monolayers (Figure 3, A and B), it would also prevent
monocyte-mediated disruption of the BBB. Integrity of the
barrier was evaluated by measuring TEER (Figure 3C).
Monocyte addition to BMVECs resulted in a 22% decrease in
TEER during the ﬁrst 4 hours (Figure 3D). CB2 agoniste
treated monocytes produced a 10% decrease at 9 hours but then
an increase to above baseline by 21 hours, whereas the TEER
of BMVEC monolayers with untreated monocytes remained
reduced by approximately 14% even at 21 hours (Figure 3D).r 21 hr
urs)
cytes
cytes (CB2 agonist-treated)
*
+ +
P1a AM1241
*
+
O-1966
Figure 3 CB2 activation reduces monocyte
adhesion to andmigration across BMVECmonolayers
and improves barrier function. Calcein-AMelabeled
primary human monocytes pretreated with CB2
agonists (10 mmol/L O-1966, JWH133 or GP1a or 2
mmol/L AM1241) were washed with PBS and added
to BMVECs. A: Fold difference of adherent cells
calculated based on a standard curve derived from
ﬂuorescence intensity of known numbers of labeled
cells. B: Fold difference in transmigrated mono-
cytes. C: TEER was measured in TNF-aepretreated
BMVECs during engagement by monocytes. Results
are from a representative experiment with the
selective CB2 agonist GP1a (10 mmol/L). D: Percent
change in TEER of BMVECs at 4, 9, and 21 hours after
addition of monocytes with or without pretreatment
with CB2 agonist. Data are expressed as means 
SEM from at least three independent experiments.
*P < 0.05 versus untreated control (at least three
replicates).
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Figure 4 CB2 activation prevents conformational activation of lympho-
cyte function-associated antigen-1 (LFA-1, integrin b2) in monocytes.
Monocytes were treated with GP1a or AM1241 (CB2 agonists) and CT04 or
NSC23766 (RhoA and Rac1 GTPase inhibitors, respectively), and the active
forms of LFA-1 were detected using the conformation-speciﬁc antibody MEM-
148. Expression of total LFA-1 (CD18) was not affected by CB2 agonists. A:
Stimulation of primary monocytes with PMA changes integrin conformation
from a closed (not active) to an open (active) form. Total amount of integrin
b2 (CD18) is shown on the x axis. B: Quantitation of integrin b2 conforma-
tional activation as percentage of cells with the activated form of the integrin
(right upper quadrant in panel A). Data are expressed as means SEM from
three independent experiments. *P < 0.05 versus untreated control.
Figure 5 CB2 activation prevents conformational activation of very late
antigen 4 (VLA-4, integrin b1) in monocytes. Monocytes were treated with
AM1241 or JWH133 (CB2 agonists) and CT04 or NSC23766 (RhoA and Rac1
GTPase inhibitors, respectively), and the active forms of VLA-4 were
detected using the conformation-speciﬁc antibody, HUTS21. Expression of
total VLA-4 (CD29) was not affected by CB2 agonists. A: Stimulation of
primary monocytes with LDV changes integrin conformation from a closed
(not active) to an open (active) form. Total amount of integrin b1 (CD29) is
shown on the x axis. B: Quantitation of integrin b1 conformational acti-
vation as percentage of cells with the activated form of the integrin (right
upper quadrant in panel A). Data are expressed as means  SEM from three
independent experiments. *P < 0.05 versus untreated control.
CB2 Attenuates Monocyte BBB MigrationIntegrin Activation Is Affected in CB2-Activated
Monocytes
Monocyte adhesion to activated endothelium is mediated by
integrins, such as VLA-4 and LFA-1, whose active confor-
mation is stimulated by insideeout or outsideein activation.The American Journal of Pathology - ajp.amjpathol.orgInsideeout activation of LFA-1 is induced by chemokine
activation of G-protein-coupled receptors and can be medi-
ated by PMA.25MEM-148 antibody boundweakly on resting
monocytes (Figure 4A), but was up-regulated on monocytes
activated by PMA (twofold). CB2 activation in PMA-
stimulated monocytes decreased expression of activated
LFA-1 by 50% to 60% (Figure 4B). Because RhoA and Rac11553
Rom et alcontrol leukocyte cytoskeleton and adhesion and migration,
we tested their speciﬁc inhibitors in parallel with CB2.
Application of the Rac1 inhibitor NSC23766 diminished the
amount of activated LFA-1 integrin by 30%, whereas the
RhoA inhibitor CT04 did not produce a signiﬁcant effect.
Surprisingly, activation of CB2with AM1241 or inhibition ofLDV - + + + + + + -
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1554both RhoA and Rac1 in monocytes up-regulated LFA-1
activation by 40% to 50%.
Exposure of monocytes to LDV, which is known to alter
VLA-4 (CD29) conformation,24 increased active integrin b1
expression threefold (Figure 5). CB2 agonists decreased
active integrin b1 expression by 10% to 17% (Figure 5).
Rac1 inhibitoretreated monocytes reduced integrin activa-
tion, whereas RhoA inhibition did not produce a signiﬁcant
effect on outsideein activation of VLA-4.
Rac1 and RhoA GTPase Activation Is Reduced in
CB2-Activated Monocytes
Because RhoA and Rac1 play critical roles in monocyte
migration, we explored the possibility that CB2 agonists
would suppress their activity in monocytes activated with
relevant stimuli. Monocyte activation by LDV peptide
increased Rac1 activity by 2.4-fold; three CB2 agonists
signiﬁcantly decreased Rac1 activity (JWH133 and GP1a by
100%, and AM1241 by 50%, respectively) (Figure 6A). No
RhoA activation was observed with LDV stimulation (data
not shown). Next, we examined whether CB2 agonists
would decrease Rac1 and RhoA activation in primary
monocytes and U937 cells stimulated by PMA. A signiﬁ-
cant increase in GTPase activation was detected in mono-
cytes stimulated with PMA (Figure 6, B and C) and
a substantial reduction was observed in the presence of CB2
agonists. PMA stimulation of U937 cells and monocytes
activated RhoA and Rac1 2.0- to 2.5-fold (Figure 6, B and
C); CB2 stimulation diminished their activation in a manner
similar to that of primary monocytes. Rac1 or RhoA
inhibitor treatment resulted in total inhibition of the
respective GTPase. These results suggest that CB2 stimu-
lation inhibits RhoA and Rac1.
CB2 Stimulation Prevents Dephosphorylation of
Inhibitory Sites of VASP and Coﬁlin
To control and coordinate cell movement and actin ﬁlament
rearrangements, efﬁcient disassembly of pre-existing actin
ﬁlaments is necessary. We have previously demonstrated
that monocytic cells with down-regulation of Rac1 increase
phosphorylation of the inhibitory sites of the actin-binding
proteins coﬁlin and vasodilator-stimulated phosphoprotein
(VASP), which regulate conformational changes of integ-
rins.27 Because CB2 agonists decreased RhoA and Rac1Figure 6 CB2 stimulation suppresses activation of Rac1 and RhoA small
GTPases in primary monocytes. Cells were serum-starved for 24 hours (RPMI
1640e1% fetal bovine serum medium supplemented with pen-
icillinestreptomycin) and then were pretreated with CB2 agonist (10 mmol/L
JWH133 or GP1a or 2 mmol/L AM1241) before stimulation. A: Rac1 activity
under LDV stimulation was measured in primary monocytes. B and C: Rac1
and RhoA activity under PMA stimulation were measured in primary mono-
cytes (white bars) and U937 cells (black bars). The level of RhoA or Rac1
activity in nonstimulated, nontreated cells was assigned a value of 1 to
calculate the relative ratio of activation. Data are expressed as means SEM
from three independent experiments. *P < 0.05 versus untreated control.
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Figure 7 CB2 activation increases levels of p-S3-coﬁlin and p-S157-
VASP. U937 cells were treated with CB2 agonist (10 mmol/L JWH133 or
GP1a or 2 mmol/L AM1241) before stimulation with LDV (A), CCL2, (B) or
PMA (C). Densitometry of phosphorylated bands was normalized to
b-tubulin. The level of phosphorylation in nonecross-linked cells was
assigned a value of 1 to calculate the relative ratio. Data are expressed as
means  SEM from three independent experiments. *P < 0.05 versus
untreated control.
CB2 Attenuates Monocyte BBB Migrationactivation, we evaluated changes in the phosphorylated
inhibitory sites of coﬁlin and VASP after stimulation with
LDV, PMA, or CCL2 in the presence of CB2 agonists
(Figure 7). Because U937 cells exhibit a response in
GTPase activation similar to that of primary monocytes, we
used them for Western blotting. LDV stimulation reduced
inhibitory VASP phosphorylation by 42%, which was
increased by 80% to 90% by CB2 agonists. Similar effects
on p-VASP were observed by inhibition of RhoA or Rac1 in
LDV-stimulated monocytes (Figure 7A). PMA stimulation
decreased p-coﬁlin by 23%, which was up-regulated by
50  4% after treatment with the CB2 agonists GP1a and
AM1241 and by 200% after JWH133 treatment (Figure 7C).
To mimic the signaling events that occur in the cell during
migration, we stimulated monocytes with the monocyte
chemoattractant protein CCL2 (Figure 7B), which produced
p-coﬁlin changes similar to that of monocytes stimulated
with LDV or PMA during CB2 activation.
Next, we tested whether LDV, CCL2, or PMA stimulation
results in a decrease in p-VASP (Figure 7). All three stimuli
decreased p-VASP, and treatment with CB2 agonists
increased phosphorylation of S157-VASP by 30% to 50% in
LDV-, CCL2-, or PMA-stimulated monocytes (Figure 7).
Application of a RhoA-speciﬁc inhibitor had similar effects
on S157-VASP phosphorylation in LDV-stimulated or non-
stimulated cells, whereas the addition of a Rac1 inhibitor
affected phosphorylation levels of S157-VASP only in LDV-
stimulated monocytes (Figure 7A). Taken together, these
results suggest that CB2 activation affects the actin-binding
proteins VASP and coﬁlin via RhoA and Rac1 inhibition.
Lamellipodia Formation Is Diminished in
CB2-Activated Monocytes
Formation of lamellipodia is necessary for leukocyte
migration associated with recruitment of active Rac1 or
RhoA into the leading or lagging edge of the cell, respec-
tively.36,37 To evaluate the possibility that CB2 activation
affects lamellipodia formation, monocytes were visualized
and lamellipodia area was measured (Figure 8). LDV and
CN04 stimulation resulted in a 2.0- to 2.3-fold increase in
lamellipodia area, and CCL2 or PMA stimulation led to
a respective 125  6% or 110  10% increase in lamelli-
podia formation. After treatment of monocytes with CB2
agonist, lamellipodia area was reduced by 70% to 100%
(Figure 8B). After inhibition of either Rac1 or RhoA,
lamellipodia area was similar to that of resting monocytes.
These data indicate that CB2 activation diminishes lamel-
lipodia formation in monocytes via inhibition of small
GTPases.Discussion
Leukocyteeendothelium interaction is at the heart of many
inﬂammatory responses. Inﬁltration of monocytes across theThe American Journal of Pathology - ajp.amjpathol.orgBBB plays an important role in various neuroinﬂammatory
conditions, including multiple sclerosis, ischemiae
reperfusion injury, and experimental autoimmune encepha-
lomyelitis. Application of CB2 agonists has been shown to
reduce leukocyte adhesion.31e33,38,39 However, these
studies did not address how much of the effects of CB2
activation apply to immune cells or endothelium (or both),
nor did they address the underlying mechanisms. In the
present study, we used IVM to test the effects of CB2
agonists on leukocyte adhesion to vascular walls in an LPS-
induced encephalitis model, in which leukocytes isolated
from mice were treated with CB2, labeled with calcein-AM
ex vivo, and injected into LPS-treated animals. CB2 acti-
vation in leukocytes signiﬁcantly inhibited leukocyte
adhesion to endothelium in cortical vessels (Figure 1),
whereas autologous cells did not show any change in
adhesion (Supplemental Figure S2). CB2ko animals showed
higher levels of inﬂammation, compared with WT mice
(Supplemental Figure S4). Adoptive transfer of CB2ko1555
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Figure 8 Effects of CB2 activation on lamellipodia formation. A:
Images of primary monocytes stained with Acti-stain 488 ﬂuorescent
phalloidin (Cytoskeleton). Protruding lamellipodia are indicated by
arrowheads. B: Average lamellipodium area (pixels) per cell (20 cells per
treatment) was calculated. Primary monocytes were left untreated or were
treated with CB2 agonist (10 mmol/L JWH133 or GP1a or 2 mmol/L
AM1241), CT04 RhoA inhibitor (1 mg/mL), or NSC23766 Rac1 inhibitor (75
mmol/L), with or without stimulation. CN04 GTPase activator (1 mg/mL)
was used as a positive control. Data are expressed as means  SEM from
two independent experiments. **P < 0.01 versus untreated control. Scale
bar Z 5 mm.
Rom et alleukocytes resulted in an increased number of adherent
leukocytes in both WT and CB2ko mice (Figure 2).
Enhanced adhesion of monocytes to TNF-aestimulated
BMVECs and their migration across BMVEC monolayers
were attenuated in CB2 agonist-treated monocytes. Inability
of CB2-activated monocytes to attach and migrate through
the endothelial layer resulted in attenuation of BBB
disruption, as demonstrated by TEER analysis (Figure 3).
Cannabinoids are able to inhibit chemokine-induced
chemotaxis of a variety of cell types, including neutro-
phils, lymphocytes, macrophages, monocytes, and micro-
glia.7 However, the mechanism or mechanisms leading to
such inhibition have not been identiﬁed.1556Small GTPases (Rho, Rac, and Cdc42) play an important
role in transendothelial leukocyte migration, oxidative
stress, and inﬂammation by linking surface receptors and the
actin cytoskeleton.40,41 In leukocytes, Rac1 and Cdc42
regulate cell polarity, lamellipodia formation, and direct
migration, whereas RhoA controls leukocyte tail retraction
during transmigration.42 We therefore measured RhoA and
Rac1 activation after stimulation with LDV peptide or PMA
in monocytes and in U937 cells, and observed a decrease in
active GTPases after CB2 stimulation. The increase in
activation of RhoA and Rac1 during migration was atten-
uated by CB2 agonists.43
Because we observed diminished adhesion of monocytes
treated with CB2 agonists, we explored the idea that CB2
stimulation results in conformational changes of active
integrin and/or total integrin expression. LDV stimulation
led to a threefold increase in conformationally active VLA-4
in primary monocytes. CB2 activation and Rac1 inhibition
resulted in diminution of active integrin b1 (Figure 5, A and
B), but expression of total VLA-4 was not changed after
treatment, indicating the importance of VLA-4 conforma-
tional status. Memory T cells constitutively expressing
activation/ligand-induced epitopes on b1 integrins recog-
nized by HUTS21 exhibit signiﬁcantly higher rates of
attachment and accumulation on VCAM-1 expressing cells,
compared with other T-cell subsets without active epitope
expression.44 The unbending of integrin leading to confor-
mational activation presumably exposes the VCAM-1
binding site,45 which facilitates both tethering and roll-
ing.46 Chigaev et al24 reported that the rate of HUTS21
binding is related to VLA-4 activation state. We have
previously reported that, on treatment with speciﬁc GSK3b
or Rac-1 inhibitors, expression of active VLA-4 is decreased
by 40% to 60% in LDV-stimulated monocytes.27 Ferreira
et al47 reported a link between conformational VLA-4
activation and Rac1, which was correlated with decreased
THP-1 monocytic cell migration.
Insideeout activation of LFA-1 was induced by PMA in
primary monocytes; Rac1 inhibition and CB2 activation
decreased LFA-1 conformational change by 30% to 50%,
whereas RhoA inhibition had no effect (Figure 4A).
Pretreatment of monocytes with both CB2 agonists and
RhoA or Rac1 inhibitors resulted in unexpected LFA-1
activation. Type I leukocyte adhesion deﬁciency is caused
by mutations in the b2-subunit of LFA-1, preventing LFA-1
surface expression,48 which is triggered by Rho signaling.49
Semmrich et al22 reported that expression of constitutively
active LFA-1 in mice resulted in impaired migration of
lymphocytes.
Whether a cell is circulating within the blood or migrating
through tissues, the leukocyte cytoskeleton undergoes
signiﬁcant changes. Actin-binding proteins, such as coﬁlin
and VASP, regulate rearrangements for these different cell
states.50 VASP is involved in ﬁlopodia formation, and p-
S157-VASP level is associated with impaired binding to
focal adhesion proteins, such as vinculin, paxillin, andajp.amjpathol.org - The American Journal of Pathology
CB2 Attenuates Monocyte BBB Migrationtalin.51 During insideeout activation of integrins, dephos-
phorylation of VASP allows its binding to talin, which in
turn allows integrin activation.52 Our present ﬁndings
demonstrate that CB2 activation in monocytes results in
increased p-S157-VASP levels. Several studies have
demonstrated that the inability to dephosphorylate S157-
VASP inhibits neutrophil and monocyte migration, as well
as associated integrin regulation.27,53 Coﬁlin causes disas-
sembly of actin ﬁlaments to monomers, so that they can be
recycled. Coﬁlin activity is inhibited by the phosphorylation
of S3; it is known that coﬁlin phosphorylation drastically
changes in response to extracellular stimuli and during cell
migration and morphogenesis.54 We therefore tested the
effects of CB2 activation on p-S3-coﬁlin levels in U937
cells and found increased levels of p-S3-coﬁlin in CB2
agonist-treated cells (Figure 7). Speciﬁc RhoA and Rac1
inhibitors showed similar results.
Actin cytoskeletal reorganization plays a central role in
cell migration. During migration, cells display F-actinerich
lamellipodia formation toward the direction of movement.
Coﬁlin plays an essential role in lamellipodia formation by
stimulating actin ﬁlament disassembly near the pointed
ends, thereby supplying actin monomers for polymeriza-
tion.55 Stimulation of Rho GTPases by CCL2, PMA, or
LDV resulted in increased lamellipodia formation in
monocytes, whereas CB2 activation in monocytes led to
signiﬁcant inhibition in lamellipodia formation. Application
of speciﬁc RhoA and Rac1 inhibitors yielded similar results,
further indicating their involvement in this process.
Taken together, our observations suggest that selective
CB2 activation in leukocytes affects key steps in leukocyte
engagement of brain endothelium (active integrin expres-
sion, lamellipodia formation, adhesion and migration via
GTPase inhibition, and cytoskeleton regulation) and could
thus be an attractive target for therapeutic interference in
neuroinﬂammatory disorders.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.07.033.References
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